Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBT: 2013-2025

Historic EBT for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -$68.0 million.

  • Ocular Therapeutix's EBT fell 56.01% to -$68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$247.3 million, marking a year-over-year decrease of 78.13%. This contributed to the annual value of -$165.1 million for FY2024, which is 83.96% down from last year.
  • Ocular Therapeutix's EBT amounted to -$68.0 million in Q3 2025, which was down 1.14% from -$67.2 million recorded in Q2 2025.
  • Ocular Therapeutix's 5-year EBT high stood at -$19.5 million for Q1 2022, and its period low was -$68.0 million during Q3 2025.
  • Moreover, its 3-year median value for EBT was -$40.8 million (2024), whereas its average is -$41.2 million.
  • As far as peak fluctuations go, Ocular Therapeutix's EBT increased by 10.95% in 2022, and later crashed by 115.51% in 2024.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's EBT stood at -$19.7 million in 2021, then fell by 5.38% to -$20.8 million in 2022, then declined by 9.42% to -$22.7 million in 2023, then slumped by 115.51% to -$49.0 million in 2024, then crashed by 56.01% to -$68.0 million in 2025.
  • Its EBT was -$68.0 million in Q3 2025, compared to -$67.2 million in Q2 2025 and -$63.1 million in Q1 2025.